Nivolumab/Ipilimumab Combo Nears EU Approval for Frontline RCC
The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended approval of nivolumab combined with low-dose ipilimumab as a frontline treatment for patients with intermediate- and poor-risk advanced renal cell carcinoma.
Source: OncLive